CorWave Attracts Global Talent, Strengthening Its Management Team in Preparation for Clinical Phase and Industrial Ramp Up
Two seasoned industry experts are joining the company: Paul Cornelison (USA) as Vice President, Regulatory Affairs, Quality Assurance and Clinical Affairs, and Michael Webb (Australia) as Vice President, Manufacturing.
AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.
Bunnik, The Netherlands, 9 June 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), today announces that the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have both granted orphan designation status to recAP for the treatment of hypophosphatasia.
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications.